Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients

This is a phase II study to investigate the feasibility of Ultra-hypofractionated radiotherapy with or without simultaneous integrated boost for low risk breast cancer patients who have received breast conservative surgery of mastectomy.

Trial Details

NCT ID

NCT05762900

Phase

PHASE2

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

Ultra-fractionated radiation therapy

Locations (sample)

Beijing, China|39.9075,116.39723

Key Eligibility Criteria

Patients diagnosed with invasive or non-invasive breast cancer;
The patients have undergone breast-conserving surgery or mastectomy with axillary sentinel nodal biopsy or dissection;
Stage ypT0-2N0-1 (if receive neoadjuvant therapy) or stage pT0-2N0-1 (if receive upfront surgery).
No distant metastasis;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →